The primary purpose of this study is to help answer if LY2127399 is safe and effective in the
treatment of rheumatoid arthritis in participants with an inadequate response to one or more
tumor necrosis factor-alpha (TNF-α) inhibitors.
This study is comprised of 2 periods:
Period 1: 24-week blinded treatment
Period 2: 48-week post-treatment follow-up